4SC (immunology portfolio) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

4SC (immunology portfolio) General Information

Description

Immunology portfolio of 4SC. The portfolio consist of two Immunology drug development programs named IMU-366 and IMU-838 and associated intellectual property.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Martinsried
  • Germany
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Corporate Office
  • Martinsried
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

4SC (immunology portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4SC (immunology portfolio)‘s full profile, request access.

Request a free trial

4SC (immunology portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4SC (immunology portfolio)‘s full profile, request access.

Request a free trial

4SC (immunology portfolio) FAQs

  • Where is 4SC (immunology portfolio) headquartered?

    4SC (immunology portfolio) is headquartered in Martinsried, Germany.

  • What industry is 4SC (immunology portfolio) in?

    4SC (immunology portfolio)’s primary industry is Buildings and Property.

  • Is 4SC (immunology portfolio) a private or public company?

    4SC (immunology portfolio) is a Private company.

  • What is 4SC (immunology portfolio)’s current revenue?

    The current revenue for 4SC (immunology portfolio) is .

  • Who are 4SC (immunology portfolio)’s investors?

    4SC has invested in 4SC (immunology portfolio).

  • When was 4SC (immunology portfolio) acquired?

    4SC (immunology portfolio) was acquired on 28-Sep-2016.

  • Who acquired 4SC (immunology portfolio)?

    4SC (immunology portfolio) was acquired by Immunic Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process